trending Market Intelligence /marketintelligence/en/news-insights/trending/ib8qsutjltqjf5nxrhqymg2 content esgSubNav
In This List

Sunovion files application for Parkinson's disease treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Sunovion files application for Parkinson's disease treatment

Sunovion Pharmaceuticals Inc. is seeking U.S. approval for its Parkinson's medicine APL-130277 which is also known as the apomorphine sublingual film.

The Marlborough, Mass.-based company's new drug application with the U.S. Food and Drug Administration is supported by a phase 3 study of the drug.

The study demonstrated that APL-130277, which works by mimicking the action of dopamine, was better than placebo in treating so-called OFF periods experienced by 40% to 60% of Parkinson's patients, resulting in tremors, stiffness or slow movement.